<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>898</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10452993</PubmedId>
            <Abstract>Homozygous HLA-A2.1 transgenic H-2KbnullDbnull double knockout (KO) mice were created. Their potential to develop HLA-A2. 1-restricted cytolytic responses was compared with that of their classical transgenic counterparts, which still express H-2Kb, Db molecules. On cell surfaces, both strains express similar amounts of chimeric (alpha 1 alpha 2 domains of human, alpha 3 cytoplasmic domains of mouse) HLA-A2.1 molecules in noncovalent association with mouse beta 2-microglobulin. Compared with mice that are totally deprived of histocompatibility class Ia molecules (H-2KbnullDbnull double KO), the expression of HLA-A2.1 in transgenic/double KO mice resulted in sizeable increase in the periphery of CD8+ T cells with a normally diversified TCR repertoire. A biased education in favor of HLA-A2.1, ascribable to the absence of H-2 class Ia molecules, was evidenced in these transgenic/double KO mice by their improved capacity to mount HLA-restricted cytolytic responses, regardless of whether they were virally infected or injected with synthetic epitopic peptide. HLA class I transgenic, H-2 class Ia KO mice should represent useful animal models for the preclinical evaluation of vaccine formulations aiming at the induction of HLA class I-restricted CTL responses.</Abstract>
            <ArticleYear>1999</ArticleYear>
            <ArticlePages>2555-60</ArticlePages>
            <ArticleTitle>Phenotypical and functional characterization of the CD8+ T cell repertoire of HLA-A2.1 transgenic, H-2KbnullDbnull double knockout mice.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Ureta-Vidal</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Firat</LastName>
                    <ForeName>H</ForeName>
                </Author>
                <Author>
                    <LastName>Pérarnau</LastName>
                    <ForeName>B</ForeName>
                </Author>
                <Author>
                    <LastName>Lemonnier</LastName>
                    <ForeName>F A</ForeName>
                </Author>
            </Authors>
            <Affiliations>Unité d'Immunité Cellulaire Antivirale, Département SIDA-Rétrovirus, Institut Pasteur, Paris, France.</Affiliations>
            <ArticleChemicalList>H-2 Antigens;H-2K(K) antigen;HLA-A2 Antigen;Histocompatibility Antigens Class I;Peptide Fragments;HIV Reverse Transcriptase</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; CD8-Positive T-Lymphocytes(immunology; metabolism; virology); Cell Membrane(immunology; metabolism); Cytotoxicity Tests, Immunologic; H-2 Antigens(genetics); HIV Reverse Transcriptase(pharmacology); HLA-A2 Antigen(genetics); Histocompatibility Antigens Class I(biosynthesis); Humans; Immunophenotyping; Influenza A virus(immunology); Lymphocyte Count; Mice; Mice, Knockout; Mice, Transgenic; Peptide Fragments(pharmacology); T-Lymphocyte Subsets(chemistry; immunology; virology); T-Lymphocytes, Cytotoxic(immunology; virology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>163</Volume>
                <Issue>5</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>M1</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GILGFVFTL</LinearSequence>
                        <StartingPosition>58</StartingPosition>
                        <EndingPosition>66</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03485.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 2556</LocationOfData>
                <EpitopeId>20354</EpitopeId>
                <ReferenceStartingPosition>58</ReferenceStartingPosition>
                <ReferenceEndingPosition>66</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>14837</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000076</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>143</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Single dose of 1000 HA units.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GILGFVFTL</LinearSequence>
                                            <StartingPosition>58</StartingPosition>
                                            <EndingPosition>66</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03485.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Splenocytes obtained 2 wks after immunization were restimulated for 5 days with syngeneic source species-infected splenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>EL-4 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <SourceOrganismId>10000225</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GILGFVFTL</LinearSequence>
                                        <StartingPosition>58</StartingPosition>
                                        <EndingPosition>66</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03485.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Virus-restimulated splenocytes from A2.1/Kb transgenic, H-2Kb0 Db0 double knockout mice lyse peptide pulsed target EL4 cells transfected with HHD (monochain construct with A2.1/Kb and human beta-2-microglobulin). Responses in A2.1/Kb transgenic Kb+ Db+ mice are significantly lower. It was estimated by limiting dilution analysis that all the lytic activity towards the virus is directed to this epitope as seen in HLA-A2.1 humans and that roughly 10 times more peptide specific CTL precursors are found in A2.1-Kb transgenic, H-2Kb0 Db0 double knockout mice than in A2.1-Kb transgenic Kb+ Db+ mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>15930</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000076</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>122</MhcAlleleId>
                                    <MhcAlleleId>172</MhcAlleleId>
                                    <MhcAlleleId>143</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>Single dose of 1000 HA units.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>GILGFVFTL</LinearSequence>
                                            <StartingPosition>58</StartingPosition>
                                            <EndingPosition>66</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03485.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Splenocytes obtained 2 wks after immunization were restimulated for 5 days with syngeneic source species-infected splenocytes.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>EL-4 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <SourceOrganismId>10000225</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>626</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GILGFVFTL</LinearSequence>
                                        <StartingPosition>58</StartingPosition>
                                        <EndingPosition>66</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03485.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Virus-restimulated splenocytes from A2.1/Kb transgenic, H-2Kb+ Db+ mice did not lyse peptide pulsed target EL4 cells transfected with HHD (monochain construct with A2.1/Kb and human beta-2-microglobulin). Responses in A2.1/Kb transgenic Kb0 Db0 double knock-out  mice are significantly higher. It was estimated by limiting dilution analysis that in both cases all the lytic activity towards the virus is directed to this epitope, as seen in HLA-A2.1 humans, and that roughly 10 times more peptide specific CTL precursors are found in A2.1/Kb transgenic, H-2Kb0 Db0 double knockout mice than in A2.1/Kb transgenic Kb+ Db+ mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

